[go: up one dir, main page]

AR004341A1 - Vacunas contra tumores y procedimiento para su produccion. - Google Patents

Vacunas contra tumores y procedimiento para su produccion.

Info

Publication number
AR004341A1
AR004341A1 ARP960105291A ARP960105291A AR004341A1 AR 004341 A1 AR004341 A1 AR 004341A1 AR P960105291 A ARP960105291 A AR P960105291A AR P960105291 A ARP960105291 A AR P960105291A AR 004341 A1 AR004341 A1 AR 004341A1
Authority
AR
Argentina
Prior art keywords
procedure
production
vaccines against
against tumors
mhc
Prior art date
Application number
ARP960105291A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR004341A1 publication Critical patent/AR004341A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Vacuna contra tumores y procedimiento para su producción. La vacuna contra tumores contiene células tumorales de las que al menos una parte presentapor lo menos un haplotipo MHC-I del paciente en la superficie de la célula y que se cargaron conu no o varios péptidos que se fijan a la molécula de MHC-I,de modo que las células tumorales son reconocidas como extranas en el contexto con los péptidos del sistema inmune del paciente y desencadenan una respuestainmune celular. La carga seefectúa en presencia de un policatión tal como polilisina.
ARP960105291A 1995-11-23 1996-11-22 Vacunas contra tumores y procedimiento para su produccion. AR004341A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
AR004341A1 true AR004341A1 (es) 1998-11-04

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105291A AR004341A1 (es) 1995-11-23 1996-11-22 Vacunas contra tumores y procedimiento para su produccion.

Country Status (24)

Country Link
US (1) US20020085997A1 (es)
EP (1) EP0866851A1 (es)
JP (1) JP2000502052A (es)
KR (1) KR19990067653A (es)
CN (1) CN1202931A (es)
AR (1) AR004341A1 (es)
AU (1) AU720131B2 (es)
BG (1) BG62999B1 (es)
BR (1) BR9611466A (es)
CA (1) CA2238176A1 (es)
CO (1) CO4520254A1 (es)
CZ (1) CZ158998A3 (es)
EE (1) EE03778B1 (es)
HU (1) HUP0000318A3 (es)
NO (1) NO982329D0 (es)
NZ (1) NZ322910A (es)
PL (1) PL188537B1 (es)
RO (1) RO115275B1 (es)
RU (1) RU2206329C2 (es)
SK (1) SK66998A3 (es)
TR (1) TR199800912T2 (es)
TW (1) TW514530B (es)
UY (2) UY24367A1 (es)
WO (1) WO1997019169A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4600681A1 (es) † 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
WO1998033527A2 (en) * 1997-01-31 1998-08-06 Cohen Edward P Cancer immunotherapy with semi-allogeneic cells
EP0904786B1 (en) * 1997-08-22 2004-12-15 Science Park Raf S.p.A. Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
WO1999047687A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
EP1473564A4 (en) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
RU2385163C2 (ru) * 2003-08-25 2010-03-27 ОнкоМун Профилактическая противораковая вакцина
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
CA2596133C (en) * 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
EP1871166A4 (en) * 2005-03-29 2008-11-12 Univ Illinois CARCINOMAS AND THERAPEUTIC PROCEDURES
EP1806359B1 (en) * 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
JP2015533473A (ja) * 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド 個別のがんワクチン及び適応免疫細胞療法
CN109072227A (zh) 2016-03-15 2018-12-21 组库创世纪株式会社 用于免疫治疗的监测和诊断及治疗剂的设计
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
WO2020243719A1 (en) 2019-05-30 2020-12-03 Gritstone Oncology, Inc. Modified adenoviruses
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
JP2024511950A (ja) * 2021-03-12 2024-03-18 ティー－キュア バイオサイエンス，インコーポレイテッド Ｔｃｒ－ｔ療法に対する腫瘍細胞の感受性を広げるための腫瘍におけるｈｌａハプロタイプ発現の多様性の増強方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Also Published As

Publication number Publication date
UY24430A1 (es) 1997-07-01
BG102439A (en) 1999-01-29
PL326756A1 (en) 1998-10-26
NO982329D0 (no) 1998-05-22
RO115275B1 (ro) 1999-12-30
US20020085997A1 (en) 2002-07-04
AU7694796A (en) 1997-06-11
PL188537B1 (pl) 2005-02-28
CZ158998A3 (cs) 1999-06-16
SK66998A3 (en) 1998-12-02
KR19990067653A (ko) 1999-08-25
EE03778B1 (et) 2002-06-17
HUP0000318A2 (hu) 2000-06-28
JP2000502052A (ja) 2000-02-22
HUP0000318A3 (en) 2002-02-28
BG62999B1 (bg) 2001-01-31
BR9611466A (pt) 1999-05-18
WO1997019169A1 (de) 1997-05-29
RU2206329C2 (ru) 2003-06-20
TW514530B (en) 2002-12-21
AU720131B2 (en) 2000-05-25
CA2238176A1 (en) 1997-05-29
TR199800912T2 (xx) 1998-08-21
UY24367A1 (es) 2000-10-31
NZ322910A (en) 2000-05-26
CN1202931A (zh) 1998-12-23
EP0866851A1 (de) 1998-09-30
CO4520254A1 (es) 1997-10-15
EE9800161A (et) 1998-12-15

Similar Documents

Publication Publication Date Title
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
ES2104565T3 (es) Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes.
CA2033640A1 (en) Vaccines against cancer and infectious diseases
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
DK0742834T4 (da) Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle
AR248426A1 (es) Produccion de particulas incorporadas a un virus vegetal que contiene un peptido antigenico, con el fin de preparar una vacuna de virus animal.
PT1526172E (pt) Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
NO20015073D0 (no) Vaksiner
AR003125A1 (es) Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
DE69706593D1 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
ATE179614T1 (de) Herpes simplex virus vp16 impfstoffe
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
CA2182889A1 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
WO2005067460A3 (en) Epha2 vaccines
ES2144418T3 (es) Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
PT964697E (pt) Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1
AR015237A1 (es) Una composicion de membranas celulares tumorales modificadas con hapteno, metodo para obtenerlas y su uso.
ES2188802T3 (es) Vectores viricos de replicacion condicional y su uso.
NO20020615D0 (no) Vaksine
HU9200583D0 (en) Method for producing el peptides of rubeola
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи

Legal Events

Date Code Title Description
FA Abandonment or withdrawal